$NVCT
Nuvectis Pharma, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024014340 Filed on November 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.540M
YoY Change -7.78%
% of Gross Profit
Research & Development $2.819M
YoY Change -37.16%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.819M
YoY Change -37.16%
Operating Profit -$4.359M
YoY Change -29.21%
Interest Expense $206.0K
YoY Change -26.43%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.153M
YoY Change -29.37%
Income Tax
% Of Pretax Income
Net Earnings -$4.153M
YoY Change -29.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.24
COMMON SHARES
Basic Shares Outstanding 19.32M 18.65M
Diluted Shares Outstanding 17.23M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.17M
YoY Change -22.17%
Cash & Equivalents $17.20M
Short-Term Investments
Other Short-Term Assets $138.0K
YoY Change -32.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.31M
YoY Change -22.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $17.31M
Total Long-Term Assets $0.00
Total Assets $17.31M
YoY Change -22.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.261M
YoY Change -35.25%
Accrued Expenses $282.0K
YoY Change 78.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.316M
YoY Change 13.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.316M
Total Long-Term Liabilities $0.00
Total Liabilities $6.316M
YoY Change 13.27%
SHAREHOLDERS EQUITY
Retained Earnings -$67.00M
YoY Change 40.76%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.99M
YoY Change
Total Liabilities & Shareholders Equity $17.31M
YoY Change -22.26%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.153M
YoY Change -29.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.404M
YoY Change -25.8%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.457M
YoY Change 108.14%
NET CHANGE
Cash From Operating Activities -2.404M
Cash From Investing Activities
Cash From Financing Activities 1.457M
Net Change In Cash -947.0K
YoY Change -62.72%
FREE CASH FLOW
Cash From Operating Activities -$2.404M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
dei Entity Central Index Key
EntityCentralIndexKey
0001875558
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18985324
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41264
dei Entity Registrant Name
EntityRegistrantName
NUVECTIS PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2405608
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Bridge Plaza,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lee,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07024
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07024
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
614-3150
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
NVCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19320973
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17169000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19126000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
138000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
59000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
17307000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19185000
CY2024Q3 us-gaap Assets
Assets
17307000
CY2023Q4 us-gaap Assets
Assets
19185000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2261000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2771000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
282000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
415000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3773000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3798000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6316000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6984000
CY2024Q3 us-gaap Liabilities
Liabilities
6316000
CY2023Q4 us-gaap Liabilities
Liabilities
6984000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18985324
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18985324
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17418886
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17418886
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
77988000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66446000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66997000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54245000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
10991000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17307000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19185000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2819000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4486000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8422000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11115000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1540000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1672000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4976000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4916000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4359000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6158000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13398000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16031000
CY2024Q3 nvct Finance Income
FinanceIncome
206000
CY2023Q3 nvct Finance Income
FinanceIncome
277000
nvct Finance Income
FinanceIncome
646000
nvct Finance Income
FinanceIncome
393000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4153000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5881000
us-gaap Net Income Loss
NetIncomeLoss
-12752000
us-gaap Net Income Loss
NetIncomeLoss
-15638000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4153000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5881000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12752000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15638000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17230559
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17230559
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16104446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16104446
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16898040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16898040
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15341685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15341685
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14219000
CY2023Q1 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1402000
CY2023Q1 nvct Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
663000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4049000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12274000
CY2023Q2 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
950000
CY2023Q2 nvct Offering Cost On Exercise Of Preferred Investment Options
OfferingCostOnExerciseOfPreferredInvestmentOptions
770000
CY2023Q2 nvct Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
816000
CY2023Q2 nvct Offering Costs
OfferingCosts
152000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3110000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5708000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
20332000
CY2023Q3 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1134000
CY2023Q3 nvct Offering Costs
OfferingCosts
39000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1101000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5881000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
16686000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2024Q1 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1296000
CY2024Q1 nvct Offering Costs
OfferingCosts
153000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4696000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4171000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
14022000
CY2024Q2 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1262000
CY2024Q2 nvct Offering Costs
OfferingCosts
55000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1672000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4428000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
12528000
CY2024Q3 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1159000
CY2024Q3 nvct Offering Costs
OfferingCosts
49000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1457000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4153000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
10991000
us-gaap Profit Loss
ProfitLoss
-12752000
us-gaap Profit Loss
ProfitLoss
-15638000
us-gaap Share Based Compensation
ShareBasedCompensation
3717000
us-gaap Share Based Compensation
ShareBasedCompensation
3485000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
79000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-209000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-510000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
582000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-133000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-287000
nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
-25000
nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
-455000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12104000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8083000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4388000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
258000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
190000
nvct Payments Of Stock Issuance Costs Related To Initial Public Offering
PaymentsOfStockIssuanceCostsRelatedToInitialPublicOffering
341000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11192000
nvct Payments Of Issuance Costs For Warrant Exercise And Preferred Investment Option
PaymentsOfIssuanceCostsForWarrantExerciseAndPreferredInvestmentOption
371000
nvct Payments Of Stock Issuance Costs Related To Private Placement
PaymentsOfStockIssuanceCostsRelatedToPrivatePlacement
508000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7825000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14170000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1957000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2066000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19126000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19993000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17169000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22059000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1 – GENERAL:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nuvectis Pharma, Inc.  (hereafter – the “Company”) was incorporated under the laws of the State of Delaware on July 27, 2020 and commenced its principal operations in May 2021. The Company’s principal executive offices are located in Fort Lee, New Jersey.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The Company is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In May 2021, the Company entered into a worldwide, exclusive license agreement with the CRT Pioneer Fund (“CRT”) (see Note 3a). In August 2021, the Company entered into a worldwide, exclusive license agreement with the University of Edinburgh, Scotland for the Company’s second drug candidate (see Note 3a).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2022, the Company’s shares began trading on the NASDAQ under the symbol “NVCT”.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liquidity and Capital Resources</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The Company has incurred net operating losses since its inception and had an accumulated deficit of $67.0 million as of September 30, 2024. The Company had cash and cash equivalents of $17.2 million as of September 30, 2024 and has not generated positive cash flows from operations. To date, the Company has been able to fund its operations primarily through the issuance and sale of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During the three months ended September 30, 2024, the Company sold a total of 216,573 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $1.5 million at an average selling price of $6.96 per share, resulting in net proceeds of approximately $1.5 million after deducting issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During the nine months ended September 30, 2024, the Company sold a total of 965,911 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $8.1 million at an average selling price of $8.36 per share, resulting in net proceeds of approximately $7.8 million after deducting issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">Management believes that its existing cash and cash equivalents as of September 30, 2024 enable the Company to fund planned operations for at least 12 months following the issuance date of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;">The Company will need to raise additional capital in order to complete the clinical trials aimed at developing the product candidates until obtaining its regulatory and marketing approvals. There can be no assurances that the Company will be able to secure such additional financing, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce its products’ development, clinical trials, commercialization efforts or other operations, or even close down or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67000000.0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17200000
us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Use of Estimates in the Preparation of Financial Statements</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</p>
CY2024Q3 nvct Collaborative Agreement Amount Utilized From Fund Raising Commitment
CollaborativeAgreementAmountUtilizedFromFundRaisingCommitment
800000
CY2024Q3 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
CY2023Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2023 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18985324
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17418886
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17418886
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4153000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5881000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12752000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15638000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17230559
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17230559
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16104446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16104446
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16898040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16898040
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15341685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15341685
CY2024Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
18882015
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
18303912
CY2024Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1651456
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1405872
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17230559
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17230559
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16898040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16898040
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-014340-index-headers.html Edgar Link pending
0001558370-24-014340-index.html Edgar Link pending
0001558370-24-014340.txt Edgar Link pending
0001558370-24-014340-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240930.xsd Edgar Link pending
tmb-20240930x10q.htm Edgar Link pending
tmb-20240930xex31d1.htm Edgar Link pending
tmb-20240930xex31d2.htm Edgar Link pending
tmb-20240930xex32d1.htm Edgar Link pending
tmb-20240930xex32d2.htm Edgar Link pending
tmb-20240930_pre.xml Edgar Link unprocessable
tmb-20240930_lab.xml Edgar Link unprocessable
tmb-20240930_def.xml Edgar Link unprocessable
tmb-20240930_cal.xml Edgar Link unprocessable
tmb-20240930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable